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Research
bone turnover,6,7 and an increased risk of
falls and fracture.3,8,9 Supplementation with
vitamin D, its derivatives, or a combination
of vitamin D and calcium increases bone
mineral density,10,11 reduces the risk of hip
and other fragility fractures,12-15 improves








Objective:  To assess the feasibility of administering an inexpensive preparation of 
vitamin D3 100 000 IU orally 3 monthly to aged-care residents.
Design:  Prospective, controlled open-label implementation trial.
Setting:  Residential aged care, November 2003 to May 2004 (primary study).
Participants:  137 ambulant residents: 107 treated (mean age, 85 years; 79 were 
women), 30 untreated controls (mean age, 87 years; 22 were women).
ventions:  Lactose microencapsulated vitamin D3 100 000 IU orally at baseline, then 
nthly (three or more doses); untreated subjects were observed contemporaneously.
 outcome measures:  Serum levels of 25-hydroxyvitamin D [25(OH)D] at 6 months 
ared with baseline; acceptability of the program to residents and staff.
lts:  At baseline, 95% of residents assessed (n = 137) had serum 25(OH)D levels 
 the desirable range of 60–160 nmol/L. At 6 months, all treated residents (n = 98) 
ved desired levels, with the mean (±SD) 25(OH)D level increasing from 
36.4 ± 12.6 nmol/L (range, 12–75 nmol/L) at baseline to 124.0 ± 27.9 nmol/L (range, 68–
244 nmol/L). In no resident did 25(OH)D approach toxic levels. The mean serum 25(OH)D 
level remained low in the control group (n = 27): 42.8 ±18.3 nmol/L (range, 18–98 nmol/L). 
The difference between the mean 25(OH)D levels of treatment and control groups at 
6 months was 81.2 nmol/L (95% CI, 69.7–92.0 nmol/L). The cost of the supplement was 
$4 per resident per annum. Substudies showed mean trough serum 25(OH)D levels in 
the desired range at 3 months (n = 31), but below the desired range at 6 months (n = 50). 
Subjects given 3-monthly doses for up to 2 years maintained serum 25(OH)D levels 
within the desired range, with no trend toward undesirable accumulation (n = 11).
Conclusions:  Vitamin D3 100 000 IU given orally 3 monthly is a practical, safe, effective 
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and inexpensive way to meet the vitamin D3 requirements of aged-care residents.he
ins
deT  high prevalence of vitamin Dufficiency among aged-care resi-nts is well documented.1-3 Con-
tributing factors include lack of exposure to
sunlight,3 poor conversion in aged skin of
pre-vitamin D3 to vitamin D3,
4 and a paucity
of vitamin D-rich dietary items. The unde-
sirable effects of vitamin D deficiency
include reduced bone mineral density,5 high
aged-care residents.3,16,17
Despite a clear definition of unmet needs
and the availability of solutions, little has been
achieved with regard to systematic, broad-
scale approaches to vitamin D nutrition in
aged care. A policy-based approach within
aged-care facilities, subject to medical consent
to exclude those with contraindications,
should eliminate the vagaries of reliance on
individual prescriptions. Such an approach
requires an intervention that is inexpensive in
terms of both materials and staff inputs.
Our study was designed to determine the
feasibility of a program of administering an
inexpensive preparation of high-dose vita-
min D3 quarterly within a residential care
setting. We used a similar regimen to that of
Trivedi and coworkers14 who found that
4-monthly oral supplementation with
100 000 IU vitamin D3 given over 5 years
reduced fractures in community-dwelling
men and women aged over 65 years.
METHODS
Subjects
With approval from the Research Ethics
Committee of the Royal Adelaide Hospital,
residents were recruited at multiple facilities
of three aged-care organisations in South
Australia, designated A, B, and C. Managers
at all participating facilities were provided
with a 1-hour information session, and vita-
min D fact sheets and protocols. Written
informed consent was obtained from resi-
dents (or their next of kin) and their general
practitioner. Residents were excluded if they
suffered from severe dementia or a progres-
sive illness limiting life expectancy, if they
were already taking vitamin D supplements,
or if there was a contraindication as assessed
by their GP (eg, known hypercalcaemia,
renal calculi, sarcoidosis, disseminated
malignancy). Consenting residents were
allocated to the treatment or control group
at each facility sequentially on a 3 to 1
(treatment to control) basis by a research
nurse. Facilities were visited in order of
geographical convenience. The untreated
control group allowed monitoring of poss-
ible seasonal variations in dietary intake or
sunlight exposure. Treated subjects received
vitamin D3 100 000 IU 3 monthly.
Vitamin D3 preparation
The vitamin D3 preparation used was
Duphasol D3-100 dry stable CWD PhEur
(Solvay Pharmaceuticals, The Netherlands).
It was purchased in bulk from Fernz Spe-
cialty Chemicals, Villawood, NSW. The
product is essentially tasteless, has an acacia
gum matrix, a lactose coating, and is water
soluble. Individual doses of 1 g containing
100 000 IU vitamin D3 were prepared and
packaged in small glass bottles in the Royal
Adelaide Hospital pharmacy. At the aged-
care facilities, the dose was mixed with
water, juice or milk, depending on the resi-
dent’s preference, and administered orally
under nursing supervision during routine
drug rounds.
Primary study
All participants had blood taken for meas-
urement of serum 25-hydroxyvitamin D
[25(OH)D] level at baseline (November
2003) and at 6 months (May 2004). The
latter were taken 1 week after the third dose,
and in the same week for the controls.
Substudies
Additional samples were taken from treated
subjects for several substudies.
Substudy 1 (3-month trough level): Blood
from a convenience sample of about 10
residents from each of the three organisa-
tions was taken 1 week before the thirdJA • Volume 185 Number 4 • 21 August 2006 195
RESEARCH(6-month) dose to determine whether
25(OH)D levels were maintained during a
3-month dosing interval.
Substudy 2 (supplementation for 6 months,
no supplementation for 6 months): Subjects
from residential care organisations B and C
who had discontinued vitamin D3 after the
third (6-month) dose were tested at 12
months to determine the extent to which
serum 25(OH)D level declined during a
6-month dosing interval.
Substudy 3a (continuous supplementation
for 12 months) and Substudy 3b (continu-
ous supplementation for 24 months): One
residential care organisation (A) continued
vitamin D3 supplementation after the 6-
month primary study was completed. Resi-
dents received 100 000 IU vitamin D3 every
3 months for up to 2 years, with testing at
12 and 24 months. This substudy deter-
mined whether ongoing 3-monthly dosing
achieved stable serum 25(OH)D values
without undesirable accumulation.
Primary outcome measure: 
25(OH)D assay
25(OH)D level was measured by radioimm-
unoassay (IDS Ltd, Bolden, Tyne and Wear,
UK) at the Institute of Medical and Veterinary
Science (IMVS) Clinical Chemistry Labora-
tory by assessors who were blinded to the
subjects’ group allocation. The assay is stand-
ardised against 25(OH)D3 but has 75% cross-
reactivity with 25(OH)D2. The coefficient of
variance at 30 nmol/L is 8.6% and at
120nmol/L is 9.7%
Secondary outcome measure: 
consumer surveys
The acceptability of the program to residents
and staff was evaluated at 6 months by
surveys that were completed by all treated
residents (or a nurse on their behalf) and by
a staff representative from each facility.
Statistical analyses
Variables were assessed using paired and
unpaired t tests. Data are presented as
mean ± SD (range) with lower and upper




A total of 137 residents (107 treated, 30
control) from 11 facilities participated in the
study (three facilities from Organisation A,
and four each from B and C). Participants’
demographic characteristics are summarised
in Box 1. At 6 months, 10 residents had died
(seven treatment, three control), one subject
from the treatment group was not in resi-
dence due to hospitalisation, and difficulties
with venous access precluded blood testing
in another.
Baseline and 6-month serum 25(OH)D lev-
els are shown in Box 1 and Box 2. The
desirable range for serum 25(OH)D level, as
defined by the IMVS laboratory, is 60–
160nmol/L. At baseline, the means of the
control and treatment groups were similar.
Combined, these groups yielded a baseline
mean ±SD of 36.4±12.7nmol/L (range, 12–
87 nmol/L; 95% CI of the mean, 34.2–
38.5nmol/L, with 130/137 (95%) residents
being below the desirable range (<60nmol/L).
According to Vieth’s classification,18 vitamin D
deficiency was mild (25–49nmol/L) in 98
(72%) subjects, moderate (12.5–24nmol/L) in
17 (12%), and severe (<12.5nmol/L) in one
subject (0.7%).
At 6 months, after the third dose of
vitamin D3, mean serum 25(OH)D level for
the treatment group had risen significantly
(P < 0.0001; paired t test) with a change of
mean from baseline of 87.6 nmol/L (95% CI,
81.5–92.1 nmol/L). At the same time, there
was a small but statistically significant rise in
serum 25(OH)D level in the control group
(P < 0.02, paired t test), with a change of
mean from baseline of 6.4 nmol/L (95% CI,
1.23–10.6 nmol/L). The difference between
the means of the treatment and control
groups at 6 months (81.2 nmol/L; 95% CI,
69.7–92.0 nmol/L) was highly significant
(P < 0.001, unpaired t test). In the treatment
group, the number of residents with serum
25(OH)D levels within the desirable range
increased from 6 (6%) to 98 (100%). No
resident was classified as deficient, and none
had any adverse effects associated with dos-
ing. The serum 25(OH)D level for one resi-
dent was 244 nmol/L — higher than the
upper boundary of the desirable range, but
1 Characteristics of the aged-care residents in the primary study, and serum 
25-hydroxyvitamin D [25(OH)D] levels at baseline and at 6 months 
Treatment group Control group 
Baseline 
Number of residents 107 30
Mean age ±SD (range), years 85 ± 6.1 (68–99) 87 ± 5.4 (74–97)
Number (%) of women 79 (74%) 22 (73%)
Number (%) of low-care residents 90 (84%) 26 (87%)
Mean 25(OH)D ± SD (range) nmol/L 36.4 ± 12.6 (12–75) 36.4 ± 13.6 (19–87)
95% CI of mean 34.0–38.8 31.3–41.5
Six months (three doses)
Number of residents 98 27
Mean 25(OH)D ± SD (range) nmol/L 124.0 ± 27.9 (68–244) 42.8 ± 18.3 (18–98)
95% CI of mean 118.1–129.2 35.6–50.0
Percentage change in 25(OH)D levels + 241% + 17%
2 Serum 25-hydroxyvitamin D [25(OH)D] level at baseline and at 6 months — 
A: treatment group; B: control group
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RESEARCHwell below toxic levels (> 690 nmol/L).19 In
the control group, the number of residents
with serum 25(OH)D levels within the
desired range increased from one (3%) to
four (15%). According to Vieth’s criteria,18
mild vitamin D deficiency persisted in 18
(67%) and moderate deficiency in two (7%)
of these untreated residents.
Substudies
The results of the substudies are summa-
rised in Box 3, Box 4, and Box 5.
Substudy 1: All of the 31 residents who had
3-month trough levels of 25(OH)D analysed
had values in the desired range (Box 3).
Substudy 2: Of 28 subjects treated at Organi-
sation B, 25 survived to 6 months when
vitamin D supplementation was discontinued.
Of these, 18 had blood samples taken at 12
months (three had died, three refused further
blood testing and another was too ill). Of the
44 subjects treated at Organisation C, 40 sur-
vived to 6 months when vitamin D supple-
mentation was discontinued. Of these, 32 had
blood samples taken at 12 months (three had
died, three refused further testing and two
were no longer in residence). In these 50
subjects, the mean serum 25(OH)D level at 12
months was below the desirable range (Box 4).
Substudy 3a and 3b: Of 35 subjects start-
ing treatment at Organisation A (which con-
tinued the 3-monthly vitamin D supplemen-
tation beyond 6 months), 33 survived to 6
months and 31 survived to 12 months. Of
these, eight who had been in substudy 1
chose not to submit to further blood testing
and another eight had ceased the regular
supplement, leaving 15 available for testing
at 12 months (Box 5). At 2 years, of these 15
subjects, two had died, one had been dis-
charged and another was too agitated to
provide a blood sample. This left 11 treated
subjects. The mean serum 25(OH)D level
was within the desired range, with no trend
towards undesirable accumulation at both
12 and 24 months (Box 5).
Consumer surveys
There was a 100% response rate to the
surveys. Ninety-nine residents and 13 staff
members (at least one from each facility)
completed the surveys. All but one resident
found the taste of the vitamin D3 solution
acceptable. All stated the vitamin D3 solu-
tion was easy to drink and indicated a
willingness to continue the regimen. All staff
were satisfied with the information provided
and displayed an accurate understanding of
why residents were receiving the vitamin D3
supplement. All stated dosing administra-
tion could easily be incorporated into rou-
tine drug rounds on a facility-wide basis.
Staff members were unanimous in their
perception that residents, other facility staff
and GPs would accept the program and
support its continuation.
DISCUSSION
Our study confirms that vitamin D insuffi-
ciency is highly prevalent among aged-care
residents in southern Australia, and vita-
min D3 100 000 IU, given 3 monthly,
safely increases levels of serum 25(OH)D
to the desired range. The substudies sug-
gest that with ongoing supplementation,
this effect can be maintained over a 2-year
period and that a 3-monthly, but not
6-monthly, dose interval is sufficiently fre-
quent. Observations in the untreated
group indicate that, without vitamin D
supplementation, serum 25(OH)D level
remains undesirably low.
The case of the single resident who had an
increase in 25(OH)D at 6 months to above
the target range (244 nmol/L) is informative.
This woman was 87 years old and had a
body mass index of only 16.9 kg/m2.
Unknown to the investigators, she had been
given a high-energy alimentary preparation
after the study was underway, which con-
tained vitamin D3 equivalent to an addi-
tional 400 IU per day. Although a second
blood test 1 month later showed 25(OH)D
levels had fallen to an acceptable level
(168 nmol/L), this experience shows the
potential for vitamin D supplements given
concurrently to increase serum 25(OH)D
level to beyond the target range. Individuals
with low adipose mass may be especially
prone to this effect.
4 Substudy 2: 25-hydroxyvitamin D [25(OH)D] level — 
supplementation for 6 months, no supplementation 
for 6 months (n= 50)
25(OH)D level (nmol/L)
At baseline
At 6 months 
(3 doses)
At 12 months 
(3 doses)
Mean ±SD 35.7 ±11.0 115 ± 22.9 54.2 ±11.7
Range 12–61 68–183 27–80
95% CI of mean 32.5–38.8 108–121 50.9–57.6
3 Substudy 1: 3-month trough level of 25-hydroxyvitamin 
D [25(OH)D] (n= 31)
* Blood for this “trough” level was taken 3 months after the preceding (2nd) 
dose. † Blood taken 1 week after 3rd dose. ◆
25(OH)D level (nmol/L)
At baseline
At 6 months before 
3rd dose*
At 6 months 
after 3rd dose†
Mean ±SD 36.4 ±10.4 86.4 ±16.9 114.1 ± 25.4
Range 24–68 60–137 69–175
95% CI of mean 32.6–40.2 80.2–92.7 105–123
5 Substudy 3a and 3b: 25-hydroxyvitamin D [25(OH)D] level (nmol/L) after 12 and 24 months of continuous 
supplementation
25(OH)D level (nmol/L)












Mean ±SD 39.5 ±11.9 138 ±22.2 110 ±16.9 41.6 ±12.4 141 ±24.7 110±19.7 114 ±15.3 
Range 22–63 98–186 84–150 24–63 98–186 84–150 81–131
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RESEARCHOur study assessed the feasibility of
implementing a low-cost, institutionally
based approach to vitamin D nutrition in
aged-care residents, with avoidance of inap-
propriate administration. Nursing staff were
able to accommodate the quarterly dosing
readily into work flows. With the exception
of the resident described above, no prob-
lems with vitamin D3 supplementation were
encountered.
An advantage of the approach described is
its low cost, $1 per dose or $4 per resident
per year. The cost of a retail product con-
taining an equivalent dose of vitamin D3
(capsules of 1000 IU vitamin D3 for daily
ingestion) is about $50 per annum. With the
latter, there would be additional staff costs
for daily administration of tablets or cap-
sules. The Royal Adelaide Hospital supple-
ment is inexpensive enough for the aged-
care facilities to be willing to meet the cost,
making the program potentially cost neutral
for health service authorities, and could be a
requirement of nursing home accreditation.
A wider scale implementation program in
up to 2000 residents has commenced at the
participating organisations. While falls and
fracture endpoints were not measured in our
study, retrospective and prospective falls and
fracture data will be collected in this larger
study to evaluate the effect of a broader scale
intervention on these endpoints.
A potential criticism of our study is lack of
randomisation and concealment of subject
allocation in the primary study and sub-
study 1. However, in studying the effective-
ness of a policy-based approach, it is hard to
envisage how resulting biases could have
confounded, in an important way, the objec-
tive primary outcome measure — serum
25(OH)D level — as the laboratory techni-
cians were blinded to treatment allocation.
Furthermore, the subjects were not them-
selves responsible for the vitamin D3 admin-
istration.
Another potential criticism is the lack of
co-supplementation with calcium. Based on
the article by Chapuy et al12 and the interde-
pendence of vitamin D and calcium metabo-
lism, it can be argued that vitamin D3 should
only be given with calcium, preferably in the
same preparation. In support of combina-
tion formulations, it has been suggested that
the serum 25(OH)D assay can be used as a
surrogate for compliance with co-adminis-
tered calcium. However, several factors need
to be considered — the very different perio-
dicity of dosing for vitamin D and calcium,
differences in tolerance, and direct and
indirect costs. Dosing frequency can be
quarterly or less for vitamin D3, but calcium
needs to be given daily, implying greater
nursing demands.
We have shown that 3-monthly vitamin
D3 is well tolerated. In contrast, inability
to swallow large capsules and constipation
are frequent, treatment-limiting effects of
calcium supplementation. Indeed, lack of
tolerance for the calcium component of
combined vitamin D and calcium regimens
has been invoked to explain the failure of
recent community-based studies to show
benefits from long-term supplementation
with vitamin D with calcium.20 These stud-
ies contrast with the positive effect on frac-
ture risk in the long-term community-based
study of Trivedi et al,14 in which vitamin D3
was given without calcium. Our study
shows that this inexpensive approach is also
appropriate in residential aged-care.
In conclusion, vitamin D3 100 000 IU
given orally 3 monthly is a practical, safe,
effective and inexpensive way to meet vita-
min D3 requirements of aged-care residents.
ACKNOWLEDGEMENTS
The study was supported by funding from the
Australian Government Department of Health and
Ageing through a National Arthritis and Muscu-
loskeletal Conditions Improvements Grant. We
would also like to acknowledge the generous sup-
port of staff and residents of Helping Hand Aged
Care, Resthaven Incorporated and the Aged Care




Alison E R Wigg, BAppScPhysio, 
MAppScPhysio, MBA, Preventive Program 
Manager, Rheumatology Unit1
Caroline Prest, RN, Research Nurse, 
Rheumatology Unit1
Peter Slobodian, BPharm, MClinPharm, 
Specialist Pharmacist, Pharmacy Department1
Allan G Need, MD, FRACP, FRCPA, Head, 
Clinical Biochemistry,2 Clinical Associate 
Professor3
Leslie G Cleland, MD, FRACP, Director, 
Rheumatology Unit,1 Clinical Professor3
1 Royal Adelaide Hospital, Adelaide, SA.
2 Institute of Medical and Veterinary Science, 
Adelaide, SA.




1 Morris HA, Morrison GW, Burr M, et al. Vitamin D
and femoral neck fractures in elderly South Aus-
tralian women. Med J Aust 1984; 140: 519-521.
2 Sambrook PN, Cameron ID, Cumming RG, et
al. Vitamin D deficiency is common in frail
institutionalised older people in northern Syd-
ney [letter]. Med J Aust 2002; 176: 560. 
3 Flicker L, Mead K, MacInnis RJ, et al. Serum vitamin
D and falls in older women in residential care in
Australia. J Am Geriatr Soc 2003; 51: 1533-1538.
4 MacLaughlin J, Holick MF. Aging decreases the
capacity of human skin to produce vitamin D3.
J Clin Invest 1985; 76: 1536-1538.
5 Outila TA, Karkkainen MU, Lamberg-Allardt CJ.
Vitamin D status affects serum parathyroid hor-
mone concentrations during winter in female
adolescents: associations with forearm bone
mineral density. Am J Clin Nutr 2001; 74: 206-210.
6 Kipen E, Helme RD, Wark JD, et al. Bone density,
vitamin D nutrition, and parathyroid hormone
levels in women with dementia. J Am Geriatr Soc
1995; 43: 1088-1091.
7 Jesudason D, Need AG, Horowitz M, Flicker L.
Relationship between serum 25-hydroxyvitamin
D and bone resorption markers in vitamin D
insufficiency. Bone 2002; 31: 626-630.
8 Diamond T, Smerdely P, Kormas N, et al. Hip
fracture in elderly men: the importance of sub-
clinical vitamin D deficiency and hypogonadism.
Med J Aust 1998; 169: 138-141.
9 Weatherall M. A meta-analysis of 25 hydroxyvita-
min D in older people with fracture of the proxi-
mal femur. N Z Med J 2000; 113: 137-140.
10 Parfitt A. Osteomalacia and related disorders. In:
Avioli LV, Krane SM, editors. Metabolic bone
disease and clinically related disorders. Philadel-
phia: WB Saunders Company, 1990: 329-396.
11 Mithal A, Sen I, Naik V, et al. Spectacular recovery
of bone mineral density following treatment of
osteomalacia [abstract]. J Bone Miner Res 2000;
15: S577.
12 Chapuy M, Arlot M, Duboeuf F, et al. Vitamin D3
and calcium to prevent hip fractures in elderly
women. N Engl J Med 1992; 327: 1637-1642.
13 Heikinheimo RJ, Inkovaara JA, Harju EJ, et al.
Annual injection of vitamin D and fractures of
aged bones. Calcif Tissue Int 1992; 51: 105-110.
14 Trivedi DP, Doll R, Khaw KT. Effect of four monthly
oral vitamin D3 (cholecalciferol) supplementation
on fractures and mortality in men and women
living in the community: randomised double
blind controlled trial. BMJ 2003; 326: 469-472.
15 Bischoff-Ferrari HA, Willett WC, Wong JB, et al.
Fracture prevention with vitamin D supplementa-
tion: a meta-analysis of randomized controlled
trials. JAMA 2005; 293: 2257-2264.
16 Bischoff HA, Stahelin HB, Dick W, et al. Effects of
vitamin D and calcium supplementation on falls:
a randomized controlled trial. J Bone Miner Res
2003; 18: 343-351.
17 Bischoff-Ferrari HA, Dawson-Hughes B, Willett
WC, et al. Effect of vitamin D on falls: a meta-
analysis. JAMA 2004; 291: 1999-2006.
18 Vieth R. Vitamin D supplementation, 25-hydroxy-
vitamin D concentrations, and safety. Am J Clin
Nutr 1999; 69: 842-856.
19 Mason RS, Posen S. The relevance of 25-hydroxy-
calciferol measurements in the treatment of
hypoparathyroidism. Clin Endocrinol (Oxf) 1979;
10: 265-269.
20 Grant AM, Avenell A, Campbell MK, et al. Oral
vitamin D3 and calcium for secondary preven-
tion of low-trauma fractures in elderly people
(Randomised Evaluation of Calcium OR vitamin
D, RECORD): a randomised placebo-controlled
trial. Lancet 2005; 365: 1621-1628.
(Received 11 Jan 2006, accepted 28 Jun 2006) ❏198 MJA • Volume 185 Number 4 • 21 August 2006
